Combination Of Viral And Bacterial Antigens (e.g., Multivalent Viral And Bacterial Vaccine, Etc.) Patents (Class 424/201.1)
-
Publication number: 20130045228Abstract: The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer cell membrane of these cells, for the manufacture of a vaccine for protection against an infection with Lawsonia intracellularis, the vaccine being in a form suitable for systemic administration.Type: ApplicationFiled: October 22, 2012Publication date: February 21, 2013Inventor: Intervet International B.V.
-
Publication number: 20130039941Abstract: The present invention pertains to the use of Haemophilus parasuis bacteria of serotype 5 expressing an iron-restriction protein visible on a Western-blot when reacted with serum of a convalescent animal which has recovered from an infection by Haemophilus parasuis bacteria of serotype 4, the said protein not being visible on a Western-blot when Haemophilus parasuis bacteria of serotype 5 grown under iron-replete conditions, are reacted under the same conditions, in a vaccine to protect a subject animal against a disorder arising from Haemophilus parasuis serotype 4 bacteria.Type: ApplicationFiled: April 22, 2011Publication date: February 14, 2013Applicant: INTERVET INTERNATIONAL B.V.Inventors: Maarten Hendrik Witvliet, Selma Marianne Hensen, Ruud Philip Antoon Maria Segers
-
Patent number: 8372407Abstract: A method for inducing HIV antigen-specific immune responses is disclosed. The method comprises administering to a subject in need thereof a therapeutically effective amount of a chimeric fusion protein comprising: (a) a first polypeptidyl region comprising a Pseudomonas Exotoxin A (PE) binding domain and a PE translocation domain, located at the N-terminus of the fusion protein; and (b) a second polypeptidyl region with a fusion peptide of HIV gp120-C1-C5-gp41 with the amino acid sequence of SEQ ID NO: 7. A method for inducing neutralizing antibodies against HIV-1 is also disclosed.Type: GrantFiled: April 20, 2012Date of Patent: February 12, 2013Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Chao-Wei Liao, Hsiu-Kang Chang
-
Publication number: 20120328643Abstract: A composition comprising (a) Neisseria meningitidis serogroup B outer membrane vesicles (OMVs), and (b) an immunogenic component selected from other Neisseria proteins, or immunogenic fragments thereof. Component (b) preferably includes a protein from a different NmB strain from that from which the OMV of component (a) is derived. The OMVs are preferably obtained by deoxycholate extraction. Optionally, the composition may also comprise a protective antigen against other pathogens.Type: ApplicationFiled: August 21, 2012Publication date: December 27, 2012Applicant: NOVARTIS AGInventors: Mariagrazia Pizza, Rino Rappuoli, Marzia Monica Giuliani
-
Patent number: 8333980Abstract: The invention provides methods of modulating an immune response to a second antigen which entail administration of a first antigen and an immunostimulatory polynucleotide. Modulation of the immune response is generally manifested as stimulation of a Th1 response.Type: GrantFiled: November 13, 2008Date of Patent: December 18, 2012Assignee: Dynavax Technologies CorporationInventors: Gary Van Nest, Stephen F. Tuck, Joseph Eiden, Jr.
-
Publication number: 20120269847Abstract: Bordetella pertussis p69 antigen is purified by immobilised metal affinity chromatography.Type: ApplicationFiled: May 10, 2010Publication date: October 25, 2012Applicant: NOVARTIS AGInventor: Christian A. Lease
-
Patent number: 8287880Abstract: Disclosed are immunogenic composition, fusion proteins, and related methods for inducing immune response to dengue virus infection.Type: GrantFiled: May 26, 2010Date of Patent: October 16, 2012Assignee: National Health Research InstitutesInventors: Hsin-Wei Chen, Chih-Hsiang Leng, Shih-Jen Liu, Pele Choi-Sing Chong
-
Patent number: 8277816Abstract: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Bacillus anthracis. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.Type: GrantFiled: February 13, 2007Date of Patent: October 2, 2012Assignee: Fraunhofer USA, Inc.Inventors: Vidadi Yusibov, Vadim Mett, Konstantin Musiychuck, Marina Skarjinskaia
-
Publication number: 20120237536Abstract: Influenza, pneumococcus and/or RSV vaccines are administered as a combination vaccine while retaining immunogenic efficacy. This combination simplifies immunisation against these two lower respiratory tract infections. The pneumococcal vaccine ideally includes at least one pneumococcal polypeptide.Type: ApplicationFiled: September 10, 2010Publication date: September 20, 2012Applicant: NOVARTISInventors: Rino Rappuoli, Ralf Leo Clemens
-
Publication number: 20120231033Abstract: The present invention relates to pharmaceutical compositions comprising an immunizing amount of inactivated Newcastle disease and an adjuvant for use in the protection of poultry against Newcastle disease, to the use of an immunogenic amount of an inactivated Newcastle disease virus and an adjuvant for the manufacture of a booster vaccine for the vaccination of a chicken or turkey, and to a kit-of-parts comprises a container comprising an inactivated Newcastle disease virus and an adjuvant for a priming vaccination of a chicken or turkey and a container comprising an inactivated Newcastle disease virus and an adjuvant for a boosting vaccination of a chicken or turkey.Type: ApplicationFiled: November 30, 2010Publication date: September 13, 2012Inventor: Carla Christina Schrier
-
Patent number: 8241843Abstract: The present invention provides a method for modulating the complement cascade by depleting the plasma of the functional activity of complement proteins and thereby reducing or eliminating complement-mediated cell lysis. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated cell lysis and peptide mediators of inflammation. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated diseases. Methods are described herein where complement cascade, triggered by either the classical or alternative complement pathways, is prevented from effecting cell lysis and inflammation due to inhibition or depletion of one or more complement components in the serum following administration of astrovirus coat proteins or derivatives.Type: GrantFiled: May 25, 2007Date of Patent: August 14, 2012Assignee: Eastern Virginia Medical SchoolInventors: Neel K. Krishna, Kenji Cunnion
-
Publication number: 20120195937Abstract: The present invention relates to immunogenic compositions comprising capsular polysaccharide or oligosaccharide of H. influenzae B (PRP) and methods of making such compositions.Type: ApplicationFiled: February 15, 2012Publication date: August 2, 2012Inventors: Nathalie Marie-Josephe GARCON, Dominique Lemoine, Florence Emilie Jeanne Francoise Wauters
-
Publication number: 20120164170Abstract: The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain.Type: ApplicationFiled: December 20, 2011Publication date: June 28, 2012Inventors: Tsun-Yung KUO, Hsu Chung Gabriel Chen, Chung-Chin Wu, Han-Ting Chen
-
Publication number: 20120148620Abstract: The present invention relates to compositions, uses thereof, and methods of vaccinating cattle, particularly cows and heifers, against Leptospira borgpetersenii serovar hardjo (type hardjo-bovis) by using Leptospira interrogans serovar hardjo (type hardjoprajitno).Type: ApplicationFiled: December 5, 2011Publication date: June 14, 2012Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventor: Carol L. RINEHART
-
Publication number: 20120135034Abstract: This invention relates to non-integrating, non-replicating retroviral vectors that cause an immune response in an animal host when administered to the host. The vectors transduce cells in the host, where they produce virus-like particles (VLPs), which stimulate an additional immune response in the host when they are released from the cells. The vectors are non-integrating, non-replicating retroviral vectors comprising long terminal repeats, a packaging sequence, and a heterologous promoter operably linked to one or more polynucleotide sequences that together encode the structural proteins of a virus. Methods of making and using the vectors are also disclosed.Type: ApplicationFiled: March 13, 2010Publication date: May 31, 2012Inventor: Boro Dropulic
-
Publication number: 20120107348Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein.Type: ApplicationFiled: January 9, 2012Publication date: May 3, 2012Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Publication number: 20120107345Abstract: When preparing HBsAg for use in a combination vaccine, it us known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification.Type: ApplicationFiled: November 22, 2011Publication date: May 3, 2012Inventor: Mario Contorni
-
Patent number: 8168201Abstract: The present invention relates to compositions for inducing immune responses, including an antigen and a promiscuous T-cell epitope. Also provided are methods of inducing immune responses in hosts, comprising administering compositions comprising antigens and promiscuous T-cell epitopes to the host.Type: GrantFiled: April 3, 2007Date of Patent: May 1, 2012Assignee: Pfizer Canada Inc.Inventors: Leslie Hickle, Abraham Anderson, Robert C. Brown, Paul Budworth, Gordana Djordjevic, Scott Kroken, Peter Luginbuhl, Toby Richardson, Genevieve Hansen
-
Publication number: 20120093854Abstract: The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against microbiological infections, wherein the infections are caused by M. bovis and at least one further cattle relevant pathogen. The combination vaccine as described herein comprises at least one M. bovis antigen, preferably the attenuated, avirulent M. bovis as provided herewith and one or more further immunologically active components effective for the treatment and/or prophylaxis of infections caused by a further pathogen of cattle.Type: ApplicationFiled: October 22, 2009Publication date: April 19, 2012Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Michael Beck, Phillip Wayne Hayes, Jeffrey P. Knittel
-
Publication number: 20120058143Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.Type: ApplicationFiled: November 9, 2011Publication date: March 8, 2012Applicant: NOVARTIS VACCINES & DIAGNOSTICS SRLInventors: Vega MASIGNANI, Marirosa Mora, Maria Scarselli
-
Patent number: 8124103Abstract: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by influenza virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.Type: GrantFiled: February 13, 2007Date of Patent: February 28, 2012Assignee: Fraunhofer USA, IncInventors: Vidadi Yusibov, Vadim Mett, Konstantin Musiychuck
-
Patent number: 8119146Abstract: HBsAg is expressed in a Saccharomyces cerevisiae host, carrying a plasmid having a HBsAg coding sequence, wherein the plasmid includes: (1) an upstream promoter from a glyceraldehyde-3-phosphate dehydrogenase gene, for controlling expression of the HBsAg coding sequence; and (2) an ARG3 transcription terminator downstream of the HBsAg coding sequence. The plasmids may also include: (3) a LEU2 selection marker; (4) a 2? plasmid sequence; and (5) an origin of replication functional in Escherichia coli. HBsAg can be expressed in this host, and can be purified for use in the manufacture of vaccines, and in particular for the manufacture of combination vaccines and in new monovalent HBV vaccines e.g. with non-alum adjuvants.Type: GrantFiled: April 14, 2006Date of Patent: February 21, 2012Inventor: Angelica Medina-Selby
-
Publication number: 20120034262Abstract: The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.Type: ApplicationFiled: October 1, 2009Publication date: February 9, 2012Applicants: NOVARTIS AG, CORNELL UNIVERSITYInventors: Nikolaus Osterrieder, Benedikt B. Kaufer, Gopinath Raju Seetharaman, Richard Harland, Lee David Albee, II, Mayur Navnitbhai Patel
-
Patent number: 8105612Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.Type: GrantFiled: May 12, 2006Date of Patent: January 31, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Marco Soriani, Isabella Santi
-
Patent number: 8101189Abstract: An immunopotentiating composition comprising a papaya mosaic virus (PapMV), or a virus-like particle (VLP) derived from PapMV coat protein, which is capable of functioning as an adjuvant and thus potentiating an immune response in an animal is provided. The immunopotentiating composition can further comprise an immunogen, which can be fused or otherwise linked to the VLP, or not linked to the VLP. The immunopotentiating composition is capable of potentiating a humoral and/or a cellular response in the animal and is suitable for use as an adjuvant or vaccine. Methods of potentiating an immune response in an animal comprising administering to the animal an immunopotentiating composition are also provided have application in both human and veterinary medicine.Type: GrantFiled: November 3, 2006Date of Patent: January 24, 2012Assignee: Folia Biotech Inc.Inventors: Denis Leclerc, Nathalie Majeau, Constantino III Roberto Lopez-Macias, Alain Lamarre
-
Publication number: 20110318383Abstract: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DDI antigen.Type: ApplicationFiled: September 7, 2011Publication date: December 29, 2011Inventors: Chengjin HUANG, Jennifer Hess
-
Publication number: 20110305725Abstract: The present invention relates to the isolation and identification of two new strains of type 2B porcine circovirus. These two new strains of porcine circovirus may be used for the preparation of vaccine or immunogenic compositions for immunizing pigs against postweaning multisystemic wasting syndrome (PMWS). Accordingly, the invention provides methods for eliciting a protective immune response against a pathogenic porcine circovirus by administering to a pig an immunogenically effective amount of a type 2B porcine circovirus vaccine or immunogenic composition comprising at least one of the porcine circoviruses having a nucleic acid sequence as set forth in SEQ ID NOs: 1 or 2, or at least one protein from at least one of the two new type 2B strains of porcine circovirus as described herein. The invention further relates to protection of a pig from any one or more of the symptoms or sequelae associated with PMWS.Type: ApplicationFiled: March 9, 2011Publication date: December 15, 2011Applicant: WYETH LLCInventor: STEPHEN QITU WU
-
Patent number: 8067011Abstract: The present invention provides a targeted multi-layered drug delivery system for the delivery of cytotoxic agents to B-cells.Type: GrantFiled: April 9, 2007Date of Patent: November 29, 2011Assignee: Chimeros, Inc.Inventors: Claude Geoffrey Davis, Miguel A. de los Rios, Kenneth J. Oh, Timothy L. Bullock, Patrick T. Johnson, Jacek Ostrowski
-
Publication number: 20110289606Abstract: Disclosed is an in vivo equine disease model and a method of preparing the disease model for equine herpesvirus-1 neurological disease comprising a horse having a low pre-exposure level of herpesvirus-specific CTL precursors wherein the horse is experimentally infected with a neuropathogenic strain of equine herpesvirus or a mutant thereof. Also disclosed is a method of quantifying the risk factors and predicting the development of clinical neurologic signs of equine herpesvirus-1 neurological disease in a horse. Also described in the invention is the determination of the risk of developing the clinical neurologic signs by a mathematical equation. A new live, attenuated vaccine formulation is disclosed that is effective against neurologic disease due to equine herpesvirus-1.Type: ApplicationFiled: July 29, 2009Publication date: November 24, 2011Inventors: George P. Allen, Glenda Ross
-
Publication number: 20110256094Abstract: Disclosed are isolated Chlamydia trachomatis proteins, methods of fusion protein and associated antibody production, and methods of using isolated proteins and antibodies in diagnosis and detection. Also disclosed are compositions comprising isolated proteins, wherein the compositions can further comprising pharmaceutically acceptable carriers, an adjuvant and/or an immunostimulant, and methods using the pharmaceutical compositions for treating or preventing an infection by Chlamydia in a subject. The compositions may also comprise a protein or immunogenic fragment of a pathogenic organism other than Chlamydia trachomatis.Type: ApplicationFiled: October 9, 2009Publication date: October 20, 2011Applicant: BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEMInventor: Guangming Zhong
-
Publication number: 20110243976Abstract: Disclosed herein are various combinations of pneumococcal polypeptides for use in immunisation. Also disclosed herein are pneumococcal polypeptides that may be useful as single antigens. These polypeptides may optionally be used in combination with pneumococcal saccharides. The antigens may be used in pneumococcal vaccines, but may also be used as components in vaccines for immunising against multiple pathogens.Type: ApplicationFiled: August 1, 2008Publication date: October 6, 2011Inventors: Claudia Donati, Alessadro Muzzi, Vega Masignani, Fabio Bagnoli, Paolo Ruggiero, Michèle Anne Barocchi
-
Patent number: 8021670Abstract: The present invention relates to the use of an immunogenic dose of immunogenic material of Mycoplasma hyopneumoniae and an immunogenic dose of live attenuated PRRS virus for the manufacture of a vaccine, and to a vaccine kit comprising such a vaccine.Type: GrantFiled: April 6, 2007Date of Patent: September 20, 2011Assignee: Intervet International B.V.Inventors: Christa Sibilla Drexler, Maarten Witvliet
-
Patent number: 8022197Abstract: The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.Type: GrantFiled: September 16, 2004Date of Patent: September 20, 2011Assignees: Tokyo Metropolitan Organization for Medical Research, Toray Industries Inc.Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto
-
Publication number: 20110223194Abstract: A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen.Type: ApplicationFiled: March 1, 2011Publication date: September 15, 2011Inventors: Timothy Raymond HIRST, Neil Andrew Williams, Andrew Morgan, Andrew Douglas Wilson, Lucy Amber Bird
-
Patent number: 8017132Abstract: The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the CD11b receptor. The invention further relates to polypeptide derivatives suitable for eliciting an immune response in a host. The invention is more particularly directed to polypeptides derived from an adenylate cyclase protein (CyaA) either under the form of a toxin or of a toxoid, which are mutant polypeptides. Said mutant polypeptides are capable of retaining the binding activity of native CyaA to a target cell and preferably of also retaining the translocating activity of native CyaA through its N-terminal domain into target cells and furthermore have a pore-forming activity which is reduced or suppressed as compared to that of the native CyaA toxin.Type: GrantFiled: March 23, 2009Date of Patent: September 13, 2011Assignee: Institut PasteurInventors: Peter Sebo, Claude Leclerc, Adriana Osickova, Catherine Fayolle, Jiri Masin, Jan Krusek, Radim Osicka, Marek Basler
-
Patent number: 8007818Abstract: The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or oligosaccharide of H. influenzae B (PRP). Immunogenic compositions and methods of making such compositions are presented in which the PRP is surprisingly protected from immune interference by adding a polyanionic polymer (such as PLG-poly-L-glutamic acid) to the composition.Type: GrantFiled: June 14, 2004Date of Patent: August 30, 2011Assignee: GlaxoSmithKline Biologicals, S.R.Inventors: Nathalie Marie-Josephe Garcon, Dominique Lemoine, Florence Emilie Jeanne Francoise Wauters
-
Publication number: 20110206726Abstract: The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by Haemophilus influenzae and polio viruses. The present invention also relates to inclusion of antigens for protection against infections caused Hepatitis virus and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.Type: ApplicationFiled: October 23, 2009Publication date: August 25, 2011Applicant: PANACEA BIOTEC LIMITEDInventors: Rajesh Jain, Sukhjeet Singh, Lavit Jambu
-
Publication number: 20110206727Abstract: A multivalent vaccine composition that comprises a papaya mosaic virus (PapMV) component and one or more antigens is provided. The composition can further optionally comprise a Salmonella spp. porin component. The PapMV component can be PapMV or PapMV virus-like particles (VLPs). The porin component can be a Salmonella spp. OmpC, OmpF or a combination thereof, and can be combined with the PapMV component or conjugated to the PapMV component. The PapMV component in the multivalent vaccine composition functions as an adjuvant and/or an immunostimulant with respect to the one or more antigens. Use of the multivalent vaccine compositions to provide protection against a plurality of strains of a pathogen, or against more than one pathogen, are also provided.Type: ApplicationFiled: May 15, 2009Publication date: August 25, 2011Inventor: Denis Leclerc
-
Patent number: 7998487Abstract: Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.Type: GrantFiled: February 14, 2008Date of Patent: August 16, 2011Assignees: The Salk Institute for Biological Studies, The Scripps Research InstituteInventors: John Young, Anette Schneemann, Marianne Manchester, Kelly Dryden, John M. Marlett, Darly Joseph Manayani, Godfrey Jonah Anderson Rainey, Vijay Reddy, Marc E. Siladi, Heather M. Scobie, Diane Thomas, Mark Yeager
-
Patent number: 7998471Abstract: Provided are recombinant mycobacteria expressing an HIV-1 antigen and a malarial antigen. Also provided are Mycobacterium smegmatis expressing an HIV-1 antigen. Further provided are vaccines capable of inducing an immune response in a mammal against HIV-1 and the malarial pathogen. Additionally provided are methods of inducing an immune response in a mammal against HIV-1 and a malarial pathogen. Also provided are methods of inducing an immune response in a mammal against HIV-1. The methods comprise infecting the mammal with any of the above-described mycobacteria.Type: GrantFiled: January 11, 2006Date of Patent: August 16, 2011Assignees: Albert Einstein College of Medicine of Yeshiva University, Beth Israel Deaconess Medical Center, Inc., Duke UniversityInventors: William R. Jacobs, Jr., Norman L. Letvin, Mark Cayabyab, Barton F. Haynes, Hua-Xin Liao, Jae-Sung Yu, Avi-Hai Hovav
-
Publication number: 20110177117Abstract: Chimeric respiratory syncytial virus (RSV) polypeptide antigens are provided. The disclosed polypeptides include a first amino acid sequence comprising an F2 domain uncleavably joined to an F1 domain of a Respiratory Syncytial Virus (RSV) Fusion (F) protein polypeptide; and a second amino acid sequence comprising a portion of an RSV Attachment (G) protein polypeptide comprising an immunologically dominant epitope. The disclosure also provides nucleic acids that encode, and pharmaceutical compositions that contain, the chimeric RSV polypeptides, as well as methods for their production and use.Type: ApplicationFiled: July 17, 2009Publication date: July 21, 2011Inventors: Normand Blais, Patrick Rheault
-
Publication number: 20110177116Abstract: The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate occasions producers are required to assemble the cattle.Type: ApplicationFiled: November 6, 2009Publication date: July 21, 2011Inventors: Terri L. Wasmoen, Huchappa Jayappa, Randall Gene Davis, Catherine M. Peters
-
Publication number: 20110159033Abstract: The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.Type: ApplicationFiled: August 31, 2009Publication date: June 30, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Kristina J. Hennessy, Phillip Wayne Hayes
-
Publication number: 20110150770Abstract: An immunogenic composition or vaccine, and method of treatment are provided by the present invention. The immunogenic composition is useful for treating, preventing, and lessening the severity of clinical symptoms associated with disease-causing organisms in swine, utilizing one or more Porcine Teschovirus antigen(s) along with an antigen of the other disease-causing organism in swine and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 9, 2010Publication date: June 23, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Elida BAUTISTA, Dianna M. Murphy JORDAN, Axel NEUBAUER, Abby Rae PATTERSON, Michael B. Roof, Eric M. VAUGHN, Joseph G. Victoria
-
Publication number: 20110150923Abstract: The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred. The invention also provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The use of chitosan and/or detoxified ADP-ribosylating toxin adjuvants enhances anti-meningococcal mucosal immune responses and can shift the Th1/Th2 bias of the responses.Type: ApplicationFiled: February 28, 2011Publication date: June 23, 2011Inventors: Giuseppe Del Giudice, Barbara Baudner, Derek O'Hagan
-
Patent number: 7964196Abstract: A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanocparticle drug delivery system is also provided.Type: GrantFiled: May 25, 2005Date of Patent: June 21, 2011Assignee: Chimeros, Inc.Inventors: Miguel de los Rios, Kenneth J. Oh
-
Patent number: 7964197Abstract: The invention belongs to the field of animal health and in particular the causative agent of a new bacterial poultry disease, Gallibacterium. The invention provides said Gallibacterium bacteria, vaccine comprising inactivated Gallibacterium, and a method of immunizing to prevent disease in poultry.Type: GrantFiled: August 26, 2009Date of Patent: June 21, 2011Assignee: Boeringer Ingelheim Vetmedica S.A. de C.VInventors: Raul Campogarrido, Carlos Gonzalez-Hernandez, Vaithianathan Sivanandan, Maria Elena Vazquez
-
Patent number: 7959927Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosal and/or EDTA.Type: GrantFiled: November 16, 2009Date of Patent: June 14, 2011Assignee: Wyeth LLCInventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
-
Patent number: 7939086Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.Type: GrantFiled: May 22, 2009Date of Patent: May 10, 2011Assignee: Bavarian Nordic A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel
-
Patent number: 7939087Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: GrantFiled: October 29, 2001Date of Patent: May 10, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser